2^nd International Conference on Cancer Genetics and Epigenetics November 12-13, 2018 | Radisson Hotel Narita | Tokyo, Japan

Dr. Ting-Yuan (TY) TU is currently an Assistant Professor at Department of Biomedical Engineering at National Cheng Kung University (NCKU) in Taiwan. In collaboration with Singapore-MIT Alliance for Research and Technology Centre (SMART), he received his Ph.D. in Mechanobiology from National University of Singapore in 2015, in Singapore. Prior to joining NCKU, he was an Application Scientist at Clearbridge Biomedics, in which his role was focused on developing downstream assays for analysis of circulating tumor cells (CTCs) isolated from patients’ peripheral blood. In addition to studies on CTCs, another aspect of his current research interest lies in the development of better biomimetic tumor microenvironment for cancer drug discovery, such as in vitro tumor models and 3D tumor invasive co-culture microfluidic platforms.

The research interests of Dr. Tu’s lab are focused on the development of better three-dimensional (3D) biomimetic culture systems for studying the mechanics of cells and tissues. Current research directions mainly lie in utilizing in vitro tumor model for integration of microfluidics for a series of development of platforms in cancer drug discovery. This includes development of 3D in vitro tumor model for therapeutic treatments, development of 3D co-culture invasive models using microfluidic system for small molecule drug discovery, and understating the mechanics of 3D tumor invasion and migration in hydrogel environment.

Xiaoying Cui has completed her PhD in 2004 from Harbin Medical University and Singapore General Hospital. Her postdoctoral studies are at the Queensland Brain Institute, the University of Queensland. She is currently a senior research fellow in the Neurodevelopmental Group in the Queensland Brain Institute. She has published more than 31 papers in reputed journals, which attracted over 1480 citations (Google Scholar) and has been serving as a reviewer for multiple renowned journals.

My research interest is epigenetic regulation of the development of the dopaminergic system and epigenetics in the brain tumors.

Dr. Giuseppe Lonetto is a molecular oncologist with a broad experience in cancer research. His background is in Medical Biotechnology with a Bachelor Degree obtained in 2007 at the University of Magnæ Græcia of Catanzaro (Italy). He continued his study at the University of Florence (Italy) where he pursued his Master degree in Medical Biotechnology and the PhD studies in Clinical Physiopathology in 2009 and 2013, respectively. Being affiliated to the Department of Critical Care he was exposed to both basic science and a clinical environment. His main scientific interest was the progression of prostate cancer under hypoxia and the role of pathways normally activated in stem cells in the progression of prostate cancer. This led him to appreciate from close distance the benefit of translating discoveries from “the bench (basic science) to bed (patients)”. He continued his education as a Postdoctoral fellow at the Molecular Cell Biology Department of the Weizmann Institute of Science (Israel) and he is currently Intern Research Scientist in the same institute. In this period of his career, he had the privilege to interact with top scientists in the field that boosted his interest and will to study and understand cancer biology.

Metabolic alterations of Cancer Cells and the role played by Stem Cells and development-related pathways in Cancer progression. His long-term goal is to penetrate the clinic with a breakthrough that will help oncological patients care and treatment.